#United States #financial results #Pleasanton #Atera #10x Genomics

Overview of 10x Genomics Q1 2026 Financial Performance

10x Genomics, Inc. (Nasdaq: TXG), a prominent player in the field of single cell and spatial biology, has shared its financial outcomes for the first quarter ending March 31, 2026. The data paints a picture that combines both hurdles and significant strides for the company as it continues to innovate and adapt in the competitive biotech landscape.

Financial Highlights

During the first quarter of 2026, 10x Genomics reported revenues totaling $150.8 million. This figure represents a 3% decline when compared to the same period last year. However, when excluding the one-time royalty revenue of $16.8 million from the previous year, the company actually saw a 9% uptick in revenue. Notably, gross margins improved to 70%, up from 68% from the previous year, attributed to reduced warranty costs and lowered inventory write-downs.

Despite facing these revenue challenges, the company recorded a significant increase of $112.9 million in cash, cash equivalents, and marketable securities, bringing the total to $539.8 million. CEO Serge Saxonov expressed optimism, highlighting the strong growth in Single Cell consumables and Spatial consumables revenue, both experiencing double-digit increases in volume.

Major Developments

The Launch of Atera

A key event in the quarter was the introduction of Atera, a cutting-edge platform designed to revolutionize biological measurements. Atera aims to facilitate spatial whole-transcriptome analysis with the precision of single-cell sensitivity, marking a major milestone in 10x Genomics' product offerings. The company anticipates that shipments of Atera will commence in the latter half of 2026, generating excitement among potential clients.

Partnership with Bioptimus

10x Genomics also entered a partnership with Bioptimus, a global biotech firm specializing in artificial intelligence. This collaboration focuses on launching STELA, an initiative aimed at producing extensive spatial datasets that correlate biological processes with disease outcomes. The STELA project will kick off utilizing the existing Xenium platform and is set to expand to Atera over time.

Operating Performance

In terms of operational efficiency, 10x Genomics successfully reduced operating expenses, reporting $123.2 million for Q1 2026, down from $144.8 million a year earlier. This reduction was primarily due to decreased legal expenditures and personnel costs. Additionally, the operating loss shrank to $17 million, compared to $39.3 million in the previous year's quarter. Similarly, the net loss reduced to $13.5 million from $34.4 million.

Outlook for 2026

For the entirety of 2026, 10x Genomics maintains its revenue guidance between $600 million and $625 million, representing flat to a maximum of 4% growth compared to the previous year. This outlook excludes any one-time revenues from patent litigation settlements noted in 2025. Serge Saxonov's reflections on the solid start to the year suggest that 10x Genomics is poised to continue its innovative journey and respond effectively to market demands.

Conclusion

The Q1 results for 2026 showcase 10x Genomics' resilience in the face of challenges, supported by exciting new product launches and strategic partnerships. As the company moves forward, focus on maintaining robust revenue streams while enhancing profit margins will be critical to its sustained growth in the evolving field of life sciences. To further engage with 10x Genomics' developments, investors and interested parties can follow their upcoming conference call scheduled for May 7, 2026, at 1:30 PM Pacific Time, available via webcast on their investor relations site.